Overview Effects of HQK-1001 in Patients With Sickle Cell Disease Status: Terminated Trial end date: 2013-12-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the effects of HQK-1001 on Hb F in subjects with sickle cell disease. Phase: Phase 2 Details Lead Sponsor: HemaQuest Pharmaceuticals Inc.